US$ 22.56
cancer risk with semaglutide Can obesity meds also reduce risk? A retrospective study of 1.1M patients found GLP-1 drugs, especially semaglutide, significantly lower risks for multiple cancers. But not all were equale: liraglutide was linked Is there an increased risk
Description
Fuel Whats Next
Mounjaro is a dual GIP and GLP-1 receptor agonist

How do GLP-1 injections work in the body

aggressive tumors often use FAK signaling to invade surrounding tissue and seed metastases (secondary tumors) By boosting FAKpaxillin activity, BPC-157 might unwittingly give any lurking cancer cells a survival or migration advantage

Secher et al

Our Team Meet Your Care Team Harold Hidalgo, PA-C Provider Jessica Daly, APRN Provider Sophia Mosleh, PA-C Provider Sabrina Bryan Clinical Staff Stephanee Aggor Clinical Staff Sofia Nava Clinical Staff Colin Melton Clinical Staff Jaslyn Jimenez Clinical Staff Maria Somado Clinical Staff Arabella Williams Clinical Staff Nicole Balkcom, RN Office Staff Questions
